NASDAQ:ALDR

Alder Biopharmaceuticals Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$18.88
0.00 (0.00 %)
(As of 10/22/2019)
Add
Compare
Today's Range
$18.88
$18.88
50-Day Range
$18.88
$18.88
52-Week Range
$8.39
$19.12
VolumeN/A
Average Volume5.12 million shs
Market Capitalization$1.58 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.64

Receive ALDR News and Ratings via Email

Sign-up to receive the latest news and ratings for Alder Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Alder Biopharmaceuticals logo

About Alder Biopharmaceuticals

Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.22 out of 5 stars

Medical Sector

1150th out of 1,351 stocks

Pharmaceutical Preparations Industry

558th out of 664 stocks

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Alder Biopharmaceuticals (NASDAQ:ALDR) Frequently Asked Questions

What stocks does MarketBeat like better than Alder Biopharmaceuticals?

Wall Street analysts have given Alder Biopharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Alder Biopharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Alder Biopharmaceuticals' earnings last quarter?

Alder Biopharmaceuticals Inc (NASDAQ:ALDR) announced its earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.01.
View Alder Biopharmaceuticals' earnings history
.

Who are Alder Biopharmaceuticals' key executives?

Alder Biopharmaceuticals' management team includes the following people:
  • Dr. John A. Latham, Co-Founder & Chief Scientific Officer (Age 59)
  • Mr. Larry K. Benedict, Principal Accounting Officer & Exec. VP (Age 58)
  • Dr. Jeffrey T. L. Smith, Managing Director of Alder Biopharmaceuticals Limited (Age 59)
  • Mr. Robert W. Azelby, Pres, CEO & Director (Age 51)
  • Mr. Carlos Campoy, Chief Financial Officer

What other stocks do shareholders of Alder Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alder Biopharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), (CPXX) (CPXX), Micron Technology (MU), (CELG), Gilead Sciences (GILD), Alibaba Group (BABA), Synergy Pharmaceuticals (SGYP), Sarepta Therapeutics (SRPT) and Celldex Therapeutics (CLDX).

What is Alder Biopharmaceuticals' stock symbol?

Alder Biopharmaceuticals trades on the NASDAQ under the ticker symbol "ALDR."

What is Alder Biopharmaceuticals' stock price today?

One share of ALDR stock can currently be purchased for approximately $18.88.

How much money does Alder Biopharmaceuticals make?

Alder Biopharmaceuticals has a market capitalization of $1.58 billion and generates $1.62 million in revenue each year. The biopharmaceutical company earns $-296,430,000.00 in net income (profit) each year or ($4.87) on an earnings per share basis.

How many employees does Alder Biopharmaceuticals have?

Alder Biopharmaceuticals employs 202 workers across the globe.

What is Alder Biopharmaceuticals' official website?

The official website for Alder Biopharmaceuticals is www.alderbio.com.

Where are Alder Biopharmaceuticals' headquarters?

Alder Biopharmaceuticals is headquartered at 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA, 98011.

How can I contact Alder Biopharmaceuticals?

Alder Biopharmaceuticals' mailing address is 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA, 98011. The biopharmaceutical company can be reached via phone at 425-205-2900 or via email at [email protected].


This page was last updated on 9/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.